We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · May 02, 2022

Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma
J. Clin. Oncol 2022 May 01;40(13)1393–1395, R Dummer, GV Long, C Robert, HA Tawbi, KT Flaherty, PA Ascierto, PD Nathan, P Rutkowski, O Leonov, C Dutriaux, M Mandalà, P Lorigan, PF Ferrucci, JJ Grob, N Meyer, H Gogas, D Stroyakovskiy, A Arance, JC Brase, S Green, T Haas, A Masood, E Gasal, A Ribas, D Schadendorf

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading